Observational analysis finds improved outcomes with site-directed therapy in oligometastatic castration-resistant prostate cancer, suggesting therapy may enhance patient survival.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yasuda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: